公开(公告)号：US20180056018A1

公开(公告)日：2018-03-01

申请号：US15689299

申请日：2017-08-29

Applicant: Cephalon, Inc.

Inventor： Janice M.G. Canvin ,  Marla D. Curran ,  Robert B. Noble ,  Saku JP Torvinen ,  James Zangrilli

IPC: A61M16/00 ,  A61M15/00 ,  A61M16/14 ,  G06F19/00 ,  C07K16/28

CPC classification number: A61M16/024 ,  A61K2039/505 ,  A61K2039/544 ,  A61M15/009 ,  A61M16/026 ,  A61M16/14 ,  A61M2016/0018 ,  A61M2016/0027 ,  A61M2202/064 ,  A61M2205/3553 ,  A61M2205/3592 ,  A61M2205/502 ,  A61M2205/505 ,  A61M2205/583 ,  A61M2205/584 ,  A61M2205/8206 ,  A61M2230/40 ,  C07K16/244 ,  C07K16/2866 ,  G06F19/325 ,  G06F19/3456 ,  G16H10/20 ,  G16H20/13 ,  G16H50/20

Abstract: Digital systems, devices and methods for managing a drug therapy, such as an anti-IL5 mAb or anti-IL5 receptor mAb treatment regimen for patients suffering from severe asthma (e.g., eosinophilic asthma), are provided. The digital systems, devices and methods may include hardware and software for predicting patient responses to a long term anti-IL5 mAb or anti-IL5 receptor mAb treatment based on clinical data obtained following an initial treatment period.